

Amendments to the Specification:

Please delete the title appearing on page 1 before the numbered lines, and replace it with the following:

-- Bleomycin or Hydroxypyridinon and Virus-Inhibiting Compound Combination Pharmaceutical Composition and Methods --

Prior to line 1 on page 1, but after the title, insert the following:

--CROSS REFERENCE TO RELATED APPLICATIONS

This application is a section 371 national entry of PCT/NL00/00559, entitled "Pharmaceutical Composition for the Treatment of Viral Infections, in Particular of the Human Immunodeficiency Virus (HIV)", and filed on August 9, 2000, which in turn claims prior to Netherlands application 1012825, entitled "Pharmaceutical Composition for the Treatment of Viral Infections, in Particular of the Human Immunodeficiency Virus (HIV)", and filed on August 13, 1999, and the specification thereof of each is incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable.

BACKGROUND OF THE INVENTION

(1) Field of the Invention.--

On page 1, following line 3, insert the following:

-- (2) Description of Related Invention --

On page 1, following line 22, insert the following:

-- BRIEF SUMMARY OF THE INVENTION --

On page 2, following line 30, insert the following:

-- BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Effect of DF on HIV-1 replication (A), cytotoxicity (B) and cellular proliferation (C) in PBL after 5 days incubation with DF.

Fig 2. Effect of L1 on HIV-1 replication (A), cytotoxicity (B) and cellular proliferation (C) in PBL after 5 days incubation with L1.

Fig 3. Effect of BLM on HIV-1 replication (A), cytotoxicity (B) and cellular proliferation (C) in PBL after 5 days incubation with BLM.

Fig. 4. Effect of DF (AI-II), L1 (BI-II) and BLM (CI-II) on HIV-1 replication (A-CI) and cytotoxicity (A-CII) in MDM after 5 days incubation.

Fig. 5. Graphical presentation of the combination index (CI) with respect to fraction affected (fa) for the p24-antigen inhabitation by a mixture of DF and ddl (molar ratio 4:1).

Fig. 6. Graphical presentation of the combination index (CI) with respect to fraction affected (fa) for the p24-antigen inhibition by a mixture of bleomycin (BLM) and ritonavir (ratio 30:1). Peripheral blood lymphocytes (PBL) were infected for 2 hours with HIV-1_{Ba-L} at an MOI of 0.001.

DETAILED DESCRIPTION OF THE INVENTION --

On page 12 in the leading before the first numbered line, amend the text as follows:

--CLAIMS--